Abstract:Osteoarthritis (OA) is the most common cause of disability worldwide among the elderly. Alarmingly, the incidence of OA in individuals less than 40 years of age is rising, likely due to the increase in obesity and post-traumatic osteoarthritis (PTOA). In recent years, due to a better understanding of the underlying pathophysiology of OA, several potential therapeutic approaches targeting specific molecular pathways have been identified. In particular, the role of inflammation and the immune system has been increasingly recognized as important in a variety of musculoskeletal diseases, including OA. Similarly, higher levels of host cellular senescence, characterized by cessation of cell division and the secretion of a senescence-associated secretory phenotype (SASP) within the local tissue microenvironments, have also been linked to OA and its progression. New advances in the field, including stem cell therapies and senolytics, are emerging with the goal of slowing disease progression. Mesenchymal stem/stromal cells (MSCs) are a subset of multipotent adult stem cells that have demonstrated the potential to modulate unchecked inflammation, reverse fibrosis, attenuate pain, and potentially treat patients with OA. Numerous studies have demonstrated the potential of MSC extracellular vesicles (EVs) as cell-free treatments that comply with FDA regulations. EVs, including exosomes and microvesicles, are released by numerous cell types and are increasingly recognized as playing a critical role in cell–cell communication in age-related diseases, including OA. Treatment strategies for OA are being developed that target senescent cells and the paracrine and autocrine secretions of SASP. This article highlights the encouraging potential for MSC or MSC-derived products alone or in combination with senolytics to control patient symptoms and potentially mitigate the progression of OA. We will also explore the application of genomic principles to the study of OA and the potential for the discovery of OA phenotypes that can motivate more precise patient-driven treatments.

Mesenchymal Stem Cell-Derived Exosomes as a Treatment Option for Osteoarthritis

Mesenchymal Stem Cells and Their Exosomes: Promising Therapeutics for Chronic Pain

Enhancement of the therapeutic efficacy of mesenchymal stem cell-derived exosomes in osteoarthritis

Mesenchymal stem cell-derived exosomes: a new therapeutic approach to osteoarthritis?

Mesenchymal stem cell-derived exosomes as a promising cell-free therapy for knee osteoarthritis

Mesenchymal Stem Cell-Derived Exosomes and Their Therapeutic Potential for Osteoarthritis

Exosomes derived from MSC as drug system in osteoarthritis therapy

Mesenchymal Stem Cell–Derived Exosomes: A Potential Therapeutic Avenue in Knee Osteoarthritis

Roles of Exosomes from Mesenchymal Stem Cells in Treating Osteoarthritis

The role and therapeutic potential of MSC-derived exosomes in osteoarthritis

Advancing Osteoarthritis Treatment: The Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes and Biomaterial Integration

Comprehensive Analysis of Therapeutic Strategies Using Mesenchymal Stem Cell-Derived Exosomes in Preclinical Models of Osteoarthritis

Mesenchymal Stem Cell‐Derived Exosomes for Effective Cartilage Tissue Repair and Treatment of Osteoarthritis

Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis

Exosome-Mediated Drug Delivery for Cell-Free Therapy of Osteoarthritis

The role of exosomes and their enhancement strategies in the treatment of osteoarthritis

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Osteoarthritis Treatment: Extracellular Matrix Protection, Chondrocyte and Osteocyte Physiology, Pain and Inflammation Management

Biomaterials-assisted exosomes therapy in osteoarthritis

Exosomes from Embryonic Mesenchymal Stem Cells Alleviate Osteoarthritis Through Balancing Synthesis and Degradation of Cartilage Extracellular Matrix

Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents

Harnessing the potential of mesenchymal stem cells-derived exosomes in degenerative diseases